OT Broadcast News

http://static.libsyn.com/p/assets/b/6/1/c/b61c042a85ef1e0b/OTBroadcastnewslogo-sm.gif

Audio-reports and interviews done in collaboration with Audio Medica and its founding Editor Peter Goodwin. Audio Medica's Audio Journal of Oncology has been bringing lively listen-in shows to members of the cancer care team in various audio formats since 1992. Scientific Editors are George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on the OTUK Editorial Board; and Gianni Bonadonna, MD, of Istituto Nazionale Tumori.

0 Likes     0 Followers     1 Subscribers

Sign up / Log in to like, follow, recommend and subscribe!

Website
http://www.oncology-times.com
Description
Audio-reports and interviews done in collaboration with Audio Medica and its founding Editor Peter Goodwin. Audio Medica's Audio Journal of Oncology has been bringing lively listen-in shows to members of the cancer care team in various audio formats since 1992. Scientific Editors are George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on the OTUK Editorial Board; and Gianni Bonadonna, MD, of Istituto Nazionale Tumori.
Language
🇬🇧 English
last modified
2017-11-26 00:03
last episode published
2010-09-13 15:49
publication frequency
25.27 days
Contributors
Explicit
false
Number of Episodes
26
Rss-Feeds
Detail page
Categories
Unsorted

Recommendations


Episodes

Date Thumb Title & Description Contributors
13.09.2010

September 2010

5.08.2010

Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'

Evangelos Terpos, speaking at the European Hematology Association 2010 Congress in Barcelona, discusses his group's encouraging findings based on 10 years of experience with thalidomide, lenalidomide, and bortezomib.
17.06.2010

From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study)

Speaking at the meeting in Barcelona,Gilles Salles of the University of Lyon discusses the results showing that patients who had achieved remissions after immunochemotherapy had only half the risk of recurrence if they also received rituximab mainte...
9.04.2010

OT Clinical Advisory Editor for Hematology/Oncology Mikkael Sekeres, MD, MS

Dr. Sekeres, Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute and Chair of the Hematology/Oncology Pharmacy& Therapeutics Committee, discusses his particular research interests of myelodysplastic syndromes and ac...
9.04.2010

OT Clinical Advisory Editor for Oncology Ramaswamy Govindan, MD

Dr. Govindan, Professor of Medicine and Director of the Thoracic Medical Oncology Program at Washington University Alvin J. Siteman Cancer Center, elaborates on his article in the April 10 issue about the promise and excitement of the new advances i...
8.04.2010

Treatment Recommendations for High-& Low-Risk Early Breast Cancer: New Data from EBCC 7, the European Breast Cancer Conference

Lori Pierce on breast-conserving therapy + adjuvant chemotherapy for BRCA 1& 2 carriers;Annette Heemskerk-Gerritsen on the relationship between contralateral mastectomy& survival; and a recommendation byAjay Sahu for a "cooling off" period f...
1.04.2010

Pregnancy& Breast Cancer: New Updates from EBCC 7, the European Breast Cancer Conference

Oncology TimesHatem Azim on how pregnancy after breast cancer is safe and possibly protective;Angela Ives on why recent -- but not current -- pregnancy worsens breast cancer prognosis; andSibylle Loibl on how chemotherapy is not generally hazardous ...
13.10.2009

Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome

John Burn talking at ECCO15-ESMO34 in Berlin about his international study showing that aspirin prevented the development of Hereditary Non-Polyposis Colon Cancer in people genetically at risk for the disease.
13.10.2009

The Disappointment of the NSABP C-08 Trial

Norman Wolmark on the study's frustrating but unequivocal results showing that bevacizumab did not extend disease-free survival in adjuvant therapy for early colon cancer at 3 years, even though there had been a benefit at 1 year. Also weighing in:N...
13.10.2009

Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!

Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer--analysis of results from the TEAM (Tamoxifen Exemestane ...
13.10.2009

Research Policy Expert: Overhaul Cancer Research Priorities Globally Now!

Richard Sullivan at ECCO15-ESMO34 on the need for research that is more “trans-national” and funded globally to shift priorities to prevention, surgical innovation and technological development, and creative, “outward branching” thinking. The need, ...
13.10.2009

Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality

Mieke Van Hemelrijck at ECCO15-ESMO34 on findings that cardiovascular mortality from heart failure and arrhythmia in addition to ischemic heart disease and myocardial infarction increased among patients treated with endocrine therapy—of whatever typ...
1.09.2009

Advanced Biliary Cancer Controlled with Cetuximab Added to GEMOX

Éveline Boucher of Centre Eugene Marquis in France on the encouraging preliminary results of her Phase II open-label study of 101 patients reported at the ESMO World Congress on Gastrointestinal Cancer
30.08.2009

Metastatic Colorectal Cancer: Capecitabine Equivalent to 5-FU in Irinotecan/Bevacizumab Combos

Michel Ducreux, Head of the GI Service at Institut Gustave Roussy, talks about the new evidence and its clinical implications, as reported in his Phase II study at the ESMO World Congress on Gastrointestinal Cancer.
15.08.2009

Stage IV Pancreatic Islet Cell Tumors: Sunitinib Doubles Progression-Free Survival in Phase III Study

Eric Raymond of Beaujon University Hospital in France discusses his study reported at the ESMO World Congress on Gastrointestinal Cancer
1.08.2009

KRAS-Driven Selection of Molecular Therapy for Metastatic Colorectal Cancer: Choosing Between Bevacizumab, Cetuximab, Panitumomab, or a Combination

Interviewed at the Palm Beach Cancer Symposium,John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles, talks about his latest data on the relevance of KRAS tumor status—i.e., whether the gene is wild-type or mutant determines the se...
30.07.2009

CML: Hagop Kantarjian on Treating Patients with the T315I Mutation

Also: (1) Feasibility of patients becoming pregnant while having TKI treatment after having stable disease for at least two years; and (2) Decreased need for allogeneic transplant.
21.07.2009

Oropharyngeal Cancer: Better Outlook with HPV-Directed Therapies

Marshall Posner, MD, talking from Palm Beach Cancer Symposium: Increased prevalence of HPV-related oropharyngeal cancers, more responsive to treatment with induction docetaxel, cisplatin,& 5-FU prior to standard chemoradiotherapy.
15.06.2009

Breast Cancer: St. Gallen Meeting Endorses Multi-Gene Assays for Refining Chemo Decision

Also from the Palm Beach Cancer Symposium,Kathy Albain, MD, talks about the St. Gallen consensus meeting’s updated recommendations about adjuvant therapy for breast cancer—i.e., endorsing the 21-gene recurrence score and 70-gene profiling assay as k...
1.06.2009

The Smartest Oncologist in the World? – Well, at least in the US!

Stanley H. Winokur, MD, on his clever, fun, and ever-evolving one-minute daily Internet quiz that lets oncologists test their knowledge& compete against others.TheSmartestOncologist.com
1.05.2009

Cancer-Related Fatigue

Paddy Stone of St. George's Hospital, University of London,& David Cella from Northwestern University Feinberg School of Medicine about the effective use of questionnaires for assessing, screening, and perhaps diagnosing cancer-related fatigue sy...
1.04.2009

Bilateral Prophylactic Mastectomy for DCIS

Todd Tuttle from University of Minnesota&Abram Recht from Beth Israel Deaconess Medical Center on the surprisingly big recent increase in the use of prophylactic bilateral mastectomy for DCIS.
6.03.2009

10th European Congress on Perspectives in Lung Cancer, Brussels

Silvia Novello andGiorgio Scagliotti on harnessing insulin-like growth factor receptor inhibition in a Phase II study that showed clinical activity of figitumumab to be at least as good as that of inhibitors of other growth factors already being use...
21.01.2009

More from the ASH Annual Meeting!

Greater Role for Umbilical Cord Blood in Adult Transplants (Mary Eapen, commentary fromArmand Keating).Ex Vivo Expansion of Cord Blood Derived Progenitor Cells: Patient Transplant Data (Colleen Delaney, commentary fromArmand Keating).Erythropoiesis-S...
20.01.2009

ASH Annual Meeting

Peter Goodwin talks to key investigatorsFrancesco Zaja (on rituximab for ITP);Hannes Wandt (on how platelet transfusions may be able to be withheld in certain patients receiving stem cell transplants for hematologic cancers); andMichael Hallek andTa...
21.12.2008

NCRI Conference, ASCO Annual Meeting, and Perspectives in Lung Cancer European Congress

New research for advanced NSCLC showing that combining monoclonal antibodies and chemotherapy can extend life: OTBN Editor Peter Goodwin and Producer Sarah Maxwell talk toRobert Pirker,Christian Manegold,Giorgio Scagliotti,Nick Thatcher, andHoward S...